# Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/FNA/zimmer-biomet-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conf-0913fd4d
Ticker: FNA
Company: Paragon 28
Source: Paragon 28
Published: 2026-07-09 00:07 EST
Original Source URL: https://ir.paragon28.com/news/default.aspx
## Summary

WARSAW, Ind., June 2, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8 with a fireside chat at

## Article Body
Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

, /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will participate in the Goldman Sachs 47 th Annual Global Healthcare Conference on Monday, June 8 with a fireside chat at 10:40 a.m. ET.

A live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com . It will be available for replay following the fireside chat.

About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet .

View original content to download multimedia: https://www.prnewswire.com/news-releases/zimmer-biomet-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conference-302787549.html

SOURCE Zimmer Biomet Holdings, Inc.
## Recent Company News
- 2026-07-09 00:07 EST — [Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026](https://biopharmsignal.com/news/FNA/zimmer-biomet-announces-quarterly-dividend-for-second-quarter-of-2026-fe05ba3b) — Source: Paragon 28
- 2026-07-09 00:07 EST — [Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/FNA/zimmer-biomet-to-present-at-the-goldman-sachs-47th-annual-global-healthcare-conf-0913fd4d) — Source: Paragon 28
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)